The Board of Directors of Vivimed Labs Limited have approved the financial results of the company for the period ended September 30, 2022 - Q2FY23, H1FY23 at its board meeting.
Vivimed Labs Ltd announces resignation of CEO and CFO
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Vivimed announces the Export of 1st shipment to Canada - Famotidine tablets 40mg and 20mg
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Vivimed announces the receipt of Government of India approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg for Indian Market
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Approval for Vivimed to manufacture Favipiravir tablets
May 10, 2021
To be used for treatment of mild to moderate cases of Covid-19
Vivimed Labs Limited, a Specialty Chemicals and Pharmaceuticals company, has announced it has received Government of India (Director General of Health Services) approval for manufacture and marketing of Favipiravir tablet of 200 mg & 400 mg under Vivimed’s own brand Favulous across India.
These are used for the treatment of mild to moderate cases of Covid-19. Favipiravir is one of the leading oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease.
Favipiravir registered highest sales in April 2021. Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd, informed the BSE: “With huge spike in Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching Favulous at a competitive price to ma